Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical
- PDF / 1,020,948 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 78 Downloads / 176 Views
Health‑related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real‑world clinical practice settings Richard W. Joseph1 · Frank Xiaoqing Liu2 · Alicia C. Shillington3 · Cynthia P. Macahilig4 · Scott J. Diede5 · Vaidehi Dave4 · Qing Harshaw2 · Todd L. Saretsky5 · Alan Simon Pickard6 Accepted: 4 May 2020 © The Author(s) 2020
Abstract Background Pembrolizumab (PEMBRO) and ipilimumab + nivolumab (IPI + NIVO) are approved advanced melanoma (AM) immunotherapies. To address limited health-related quality of life (QoL) real-world evidence with immunotherapies in AM, we compared QoL in AM patients receiving either treatment in clinical practice. Methods A prospective US observational study enrolled adult AM patients initiating first-line PEMBRO or IPI + NIVO between June 2017 and March 2018. Endpoints included the QLQ-C30 global health score (GHS) and EuroQol visual analog scale (EQ-VAS) scores. Mean changes were compared using repeated measures mixed-effects models and are presented covariate adjusted. Results 225 PEMBRO and 187 IPI + NIVO patients were enrolled. From baseline through week 24, PEMBRO was associated with 3.2 mean GHS score increase (95% CI 0.5, 5.9; p = .02), while no change was observed with IPI + NIVO; 0.2 (95% CI − 2.6, 3.0; p = 0.87). Among objective treatment-responders, GHS scores associated with PEMBRO increased 6.0 (95% CI 3.1, 8.8; p
Data Loading...
